Astria Therapeutics, Inc. financial data

Symbol
ATXS on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, 10 Th Floor, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CATABASIS PHARMACEUTICALS INC (to 8/20/2021)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.43K % -8.78%
Debt-to-equity 4.63 % +15.5%
Return On Equity -32.7 % -24.2%
Return On Assets -31.2 % -23.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.4M shares +101%
Common Stock, Shares, Outstanding 54.9M shares +96%
Entity Public Float 280M USD +994%
Common Stock, Value, Issued 55K USD +96.4%
Weighted Average Number of Shares Outstanding, Basic 56.5M shares +102%
Weighted Average Number of Shares Outstanding, Diluted 56.5M shares +102%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 30.7M USD +47.4%
Operating Income (Loss) -107M USD -94.3%
Nonoperating Income (Expense) 14.2M USD +126%
Net Income (Loss) Attributable to Parent -93.2M USD -90.2%
Earnings Per Share, Basic -2.38 USD/shares -0.85%
Earnings Per Share, Diluted -2.38 USD/shares -0.85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 87.2M USD -34.9%
Cash, Cash Equivalents, and Short-term Investments 355M USD +74.7%
Assets, Current 358M USD +75.1%
Operating Lease, Right-of-Use Asset 5.72M USD +765%
Other Assets, Noncurrent 4.39M USD +122%
Assets 368M USD +77.7%
Accounts Payable, Current 2.34M USD +182%
Employee-related Liabilities, Current 2.54M USD +46.2%
Accrued Liabilities, Current 12.8M USD +147%
Liabilities, Current 16.4M USD +148%
Operating Lease, Liability, Noncurrent 4.54M USD +8474%
Liabilities 20.9M USD +214%
Accumulated Other Comprehensive Income (Loss), Net of Tax -45K USD
Retained Earnings (Accumulated Deficit) -625M USD -17.5%
Stockholders' Equity Attributable to Parent 347M USD +73.2%
Liabilities and Equity 368M USD +77.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -44.1%
Net Cash Provided by (Used in) Financing Activities 142M USD +283%
Net Cash Provided by (Used in) Investing Activities -126M USD -165%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 54.9M shares +96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.52M USD -102%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 87.4M USD -34.9%
Deferred Tax Assets, Valuation Allowance 125M USD +20.4%
Deferred Tax Assets, Gross 125M USD +20.2%
Operating Lease, Liability 5.79M USD +800%
Payments to Acquire Property, Plant, and Equipment 5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.3M USD -91%
Lessee, Operating Lease, Liability, to be Paid 6.88M USD +920%
Operating Lease, Liability, Current 1.25M USD +111%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.58M USD +299%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.09M USD +3410%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.64M USD
Deferred Tax Assets, Operating Loss Carryforwards 85.7M USD +6.99%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD
Operating Lease, Payments 800K USD +14.3%
Additional Paid in Capital 876M USD +37.7%
Deferred Tax Assets, Net of Valuation Allowance 99K USD -61.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%